A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results.


Bavbek S. E., Malik Z., Di Lorenzo G., Scholz H., van Oort I. M., Ng S., ...More

JOURNAL OF CLINICAL ONCOLOGY, vol.30, no.5, 2012 (SCI-Expanded, Scopus) identifier